{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:25:04Z","timestamp":1793255104187,"version":"4.5.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The association of systemic sclerosis (SSc) and cancer is well known from several decades suggesting common genetic and environmental risk factors involved in the development of both diseases. Immunosuppressive drugs widely used in SSc may increase the risk of cancer occurrence and different SSc clinical and serological features identify patients at major risk to develop malignancy. In this context, among serological features, presence of anti-RNA polymerase III and anti-topoisomerase I autoantibodies seems to increase cancer frequency in SSc patients (particularly lung and breast cancers). Lung fibrosis and a long standing SSc pulmonary involvement have been largely proposed as lung cancer risk factors, and the exposure to cyclophosphamide and an upper gastrointestinal involvement have been traditionally linked to bladder and oesophagus cancers, respectively. Furthermore, immune checkpoint inhibitors used for cancer therapy can induce immune-related adverse events, which are more frequent and severe in patients with pre-existing autoimmune diseases such as SSc. The strong association between SSc and cancer occurrence steers clinicians to carefully survey SSc patients performing periodical malignancy screening. In the present review, the most relevant bilateral relationships between SSc and cancer will be addressed.<\/jats:p>","DOI":"10.1007\/s12016-022-08930-4","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:02:42Z","timestamp":1663545762000},"page":"398-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Systemic Sclerosis Association with Malignancy"],"prefix":"10.1007","volume":"63","author":[{"given":"Gemma","family":"Lepri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bellando-Randone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giommoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Giorgione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Botteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"8930_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557\u2013567","journal-title":"J Clin Invest"},{"key":"8930_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.amjmed.2004.04.031","volume":"118","author":"JP Ioannidis","year":"2005","unstructured":"Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, Kuwana M, Yasuoka H et al (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118:2\u201310","journal-title":"Am J Med"},{"key":"8930_CR3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/rheumatology\/37.7.750","volume":"37","author":"S Jacobsen","year":"1998","unstructured":"Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750\u2013755","journal-title":"Br J Rheumatol"},{"issue":"10","key":"8930_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Air\u00f2 P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809\u20131815","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8930_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0961203319899986","volume":"29","author":"HA Noureldine","year":"2020","unstructured":"Noureldine HA, Nour-Eldine W, Hodroj MH, Noureldine MHA, Taher A, Uthman I (2020) Hematological malignancies in connective tissue diseases. Lupus 29(3):225\u2013235","journal-title":"Lupus"},{"issue":"1","key":"8930_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2021","unstructured":"Volkmann ER, Fischer A (2021) Update on morbidity and mortality in systemic sclerosis\u2013related interstitial lung disease. J Scleroderma Relat Disord 6(1):11\u201320","journal-title":"J Scleroderma Relat Disord"},{"key":"8930_CR7","unstructured":"Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A et al (2017) Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76(11):1897\u20131905"},{"issue":"2","key":"8930_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","volume":"44","author":"M Rubio-Rivas","year":"2014","unstructured":"Rubio-Rivas M, Royo C, Sime\u00f3n CP, Corbella X, Fonollosa V (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44(2):208\u2013219","journal-title":"Semin Arthritis Rheum"},{"key":"8930_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T","volume":"76","author":"AK Rosenthal","year":"1995","unstructured":"Rosenthal AK, McLaughlin JK, Gridley G, Nyr\u00e9n O (1995) Incidence of cancer among patients with systemic sclerosis. Cancer 76:910\u2013914","journal-title":"Cancer"},{"key":"8930_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/art.1780360405","volume":"36","author":"M Abu-Shakra","year":"1993","unstructured":"Abu-Shakra M, Guillemin F, Lee P (1993) Cancer in systemic sclerosis. Arthritis Rheum 36:460\u2013464","journal-title":"Arthritis Rheum"},{"key":"8930_CR11","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/art.1780281204","volume":"28","author":"AD Roumm","year":"1985","unstructured":"Roumm AD, Medsger TA Jr (1985) Cancer and systemic sclerosis. An epidemiologic study Arthritis Rheum 28:1336\u20131340","journal-title":"An epidemiologic study Arthritis Rheum"},{"issue":"4","key":"8930_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1365-2133.2010.09861.x","volume":"163","author":"AB Olesen","year":"2010","unstructured":"Olesen AB, Svaerke C, Farkas DK, S\u00f8rensen HT (2010) Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 163(4):800\u2013806","journal-title":"Br J Dermatol"},{"issue":"3","key":"8930_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/jcm9030853","volume":"9","author":"L Partouche","year":"2020","unstructured":"Partouche L, Goulabchand R, Maria ATJ, Rivi\u00e8re S, Jorgensen C, Rigau V et al (2020) Biphasic temporal relationship between cancers and systemic sclerosis: a clinical series from Montpellier University Hospital and Review of the Literature. J Clin Med 9(3):853","journal-title":"J Clin Med"},{"key":"8930_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/canjclin.56.2.69","volume":"56","author":"D Schottenfeld","year":"2006","unstructured":"Schottenfeld D, Beebe-Dimmer J (2006) Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 56:69\u201383","journal-title":"CA Cancer J Clin"},{"key":"8930_CR15","first-page":"153","volume":"22","author":"PJ Roberts-Thomson","year":"2004","unstructured":"Roberts-Thomson PJ, Male DA, Walker JG, Cox SR, Shen X, Smith MD et al (2004) Genomic instability in scleroderma. Asian Pac J Allergy Immunol 22:153\u2013158","journal-title":"Asian Pac J Allergy Immunol"},{"key":"8930_CR16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3324\/haematol.11034","volume":"92","author":"G Leone","year":"2007","unstructured":"Leone G, Pagano L, Ben-Yehuda D, Voso MT (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92:1389\u20131398","journal-title":"Haematologica"},{"issue":"9","key":"8930_CR17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10067-008-0925-x","volume":"27","author":"E Szekanecz","year":"2008","unstructured":"Szekanecz E, Szamosi S, Gergely L, Keszthelyi P, Szekanecz Z, Szucs G (2008) Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol 27(9):1163\u20131166","journal-title":"Clin Rheumatol"},{"key":"8930_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/ard.52.7.531","volume":"52","author":"AK Rosenthal","year":"1993","unstructured":"Rosenthal AK, McLaughlin JK, Linet MS, Persson I (1993) Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 52:531\u2013533","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8930_CR19","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/acr.24076","volume":"72","author":"KB Morrisroe","year":"2020","unstructured":"Morrisroe KB, Hansen D, Huq M, Stevens W, Sahhar J, Ngian GS et al (2020) Incidence, Risk factors, and outcomes of cancer in systemic sclerosis. Arthritis Care Res (Hoboken) 72(11):1625\u20131635","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8930_CR20","doi-asserted-by":"crossref","unstructured":"Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S (2003) Tumors as elusive targets of T-cell-based active immunotherapy. Mechanisms of Immune Evasion by Tumors. Trends Immunol 24:334\u201341","DOI":"10.1016\/S1471-4906(03)00116-9"},{"key":"8930_CR21","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/archderm.1979.04010080014013","volume":"115","author":"SC Duncan","year":"1979","unstructured":"Duncan SC, Winkelmann RK (1979) Cancer and scleroderma. Arch Dermatol 115:950\u2013955","journal-title":"Arch Dermatol"},{"key":"8930_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/ard.62.8.728","volume":"62","author":"CL Hill","year":"2003","unstructured":"Hill CL, Nguyen AM, Roder D, Roberts-Thomson P (2003) Risk of cancer in patients with scleroderma: a population-based cohort study. Ann Rheum Dis 62:728\u2013731","journal-title":"Ann Rheum Dis"},{"key":"8930_CR23","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1002\/art.21225","volume":"52","author":"S Chatterjee","year":"2005","unstructured":"Chatterjee S, Dombi GW, Severson RK, Mayes MD (2005) Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 52:2415\u20132424","journal-title":"Arthritis Rheum"},{"key":"8930_CR24","first-page":"1113","volume":"33","author":"CT Derk","year":"2006","unstructured":"Derk CT, Rasheed M, Artlett CM, Jiminez SA (2006) A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 33:1113\u20131116","journal-title":"J Rheumatol"},{"issue":"1","key":"8930_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/SMJ.0b013e31815838ce","volume":"101","author":"M Wooten","year":"2008","unstructured":"Wooten M (2008) Systemic sclerosis and malignancy: a review of the literature. South Med J 101(1):59\u201362","journal-title":"South Med J"},{"issue":"1","key":"8930_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","volume":"52","author":"M Bonifazi","year":"2013","unstructured":"Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C et al (2013) Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 52(1):143\u2013154","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8930_CR27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/ard.2006.056424","volume":"66","author":"EK Pontifex","year":"2007","unstructured":"Pontifex EK, Hill CL, Roberts-Thomson P (2007) Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 66(4):551\u2013553","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8930_CR28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s10067-016-3288-8","volume":"35","author":"T Ka\u015fifo\u011flu","year":"2016","unstructured":"Ka\u015fifo\u011flu T, Ya\u015far Bilge \u015e, Y\u0131ld\u0131z F, \u00d6zen G, Pehlivan Y, Y\u0131lmaz N et al (2016) Risk factors for malignancy in systemic sclerosis patients. Clin Rheumatol 35(6):1529\u20131533","journal-title":"Clin Rheumatol"},{"key":"8930_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00296-009-1348-y","volume":"31","author":"K Siau","year":"2011","unstructured":"Siau K, Laversuch CJ, Creamer P, O\u2019Rourke KP (2011) Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int 31:641\u2013645","journal-title":"Rheumatol Int"},{"issue":"7","key":"8930_CR30","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/art.37969","volume":"65","author":"A Onishi","year":"2013","unstructured":"Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65(7):1913\u20131921","journal-title":"Arthritis Rheum"},{"key":"8930_CR31","doi-asserted-by":"crossref","unstructured":"Zhong H, Zhou J, Zhang S, Xu Y, Hou Y, Li M et al (2021) Risk and prognosis factors for systemic sclerosis with lung cancer: a single-centre case-control study in China. Int J Clin Pract 75(4):e13819","DOI":"10.1111\/ijcp.13819"},{"issue":"12","key":"8930_CR32","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/crj.13249","volume":"14","author":"M Chen","year":"2020","unstructured":"Chen M, Liu X, Xu Y, Zhou Q, Shi Y, Zhang D et al (2020) Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. Clin Respir J 14(12):1131\u20131136","journal-title":"Clin Respir J"},{"key":"8930_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.autrev.2012.06.003","volume":"12","author":"M Colaci","year":"2013","unstructured":"Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Vacchi C, Spagnolo P et al (2013) Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev 12:374\u2013379","journal-title":"Autoimmun Rev"},{"issue":"10","key":"8930_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.revmed.2019.06.004","volume":"40","author":"J Catano","year":"2019","unstructured":"Catano J, Guedon A, Riviere S, Carrat F, Mahevas T, Fain O et al (2019) Cancers in systemic Sclerosis: risk factors, impact on survival and literature review. Rev Med Interne 40(10):637\u2013644","journal-title":"Rev Med Interne"},{"issue":"1","key":"8930_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3109\/03009742.2011.618145","volume":"41","author":"CF Kuo","year":"2012","unstructured":"Kuo CF, Luo SF, Yu KH, Chou IJ, Tseng WY, Chang HC et al (2012) Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 41(1):44\u201349","journal-title":"Scand J Rheumatol"},{"key":"8930_CR36","first-page":"1136","volume":"12","author":"M Peters-Golden","year":"1985","unstructured":"Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM (1985) Incidence of lung cancer in systemic sclerosis. J Rheumatol 12:1136\u20131139","journal-title":"J Rheumatol"},{"issue":"12","key":"8930_CR37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.autrev.2012.02.021","volume":"11","author":"E Szekanecz","year":"2012","unstructured":"Szekanecz E, Szamosi S, Horv\u00e0th A, N\u00e9meth A, Juh\u00e0sz B, Sz\u00e0nt\u00f2 J et al (2012) Malignancies associated with systemic sclerosis. Autoimmun Rev 11(12):852\u2013855","journal-title":"Autoimmun Rev"},{"key":"8930_CR38","doi-asserted-by":"crossref","unstructured":"Peng H, Wu X, Wen Y, Li C, Lin J, Li J et al (2020) Association between systemic sclerosis and risk of lung cancer: results from a pool of cohort studies and Mendelian randomization analysis. Autoimmun Rev 19(10):102633","DOI":"10.1016\/j.autrev.2020.102633"},{"key":"8930_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.autrev.2013.09.006","volume":"13","author":"M Colaci","year":"2014","unstructured":"Colaci M, Giuggioli D, Vacchi C, Lumetti F, Iachetta F, Marcheselli L et al (2014) Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based cancer registry and review of the literature. Autoimmun Rev 13:132\u2013137","journal-title":"Autoimmun Rev"},{"issue":"9","key":"8930_CR40","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.3389\/fimmu.2018.03112","volume":"10","author":"ATJ Maria","year":"2019","unstructured":"Maria ATJ, Partouche L, Goulabchand R, Rivi\u00e8re S, Rozier P, Bourgier C et al (2019) Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors. Front Immunol 10(9):3112","journal-title":"Front Immunol"},{"issue":"6","key":"8930_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s10067-004-0940-5","volume":"23","author":"D Launay","year":"2004","unstructured":"Launay D, Le Berre R, Hatron PY, Peyrat JP, Hachulla E, Devulder B et al (2004) Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 23(6):516\u2013522","journal-title":"Clin Rheumatol"},{"key":"8930_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00005792-197903000-00006","volume":"58","author":"JH Talbott","year":"1979","unstructured":"Talbott JH, Barrocas M (1979) Progressive systemic sclerosis (PSS) and malignancy, pulmonary and non-pulmonary. Medicine (Baltimore) 58:182\u2013207","journal-title":"Medicine (Baltimore)"},{"key":"8930_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/rheumatology\/28.1.65","volume":"28","author":"AM Forbes","year":"1989","unstructured":"Forbes AM, Woodrow JC, Verbov JL, Graham RM (1989) Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 28:65\u201369","journal-title":"Br J Rheumatol"},{"key":"8930_CR44","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/0248-8663(96)82683-X","volume":"17","author":"P Bielefeld","year":"1996","unstructured":"Bielefeld P, Meyer P, Caillot D, Dalac S, Camus P, Tavernier C et al (1996) Systemic scleroderma and cancers: 21 cases and review of the literature (in French). Rev Med Interne 17:810\u2013813","journal-title":"Rev Med Interne"},{"issue":"10","key":"8930_CR45","first-page":"2265","volume":"26","author":"C Darras-Joly","year":"1999","unstructured":"Darras-Joly C, Wechsler B, Bl\u00e9try O, Piette JC (1999) De novo systemic sclerosis after radiotherapy: a report of 3 cases. J Rheumatol 26(10):2265\u20132267","journal-title":"J Rheumatol"},{"issue":"6","key":"8930_CR46","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/jpm11060580","volume":"11","author":"A Toss","year":"2021","unstructured":"Toss A, Spinella A, Isca C, Vacchi C, Ficarra G, Fabbiani L et al (2021) Clinical and pathological features of breast cancer in systemic sclerosis: results from the Sclero-Breast Study. J Pers Med 11(6):580","journal-title":"J Pers Med"},{"key":"8930_CR47","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Acebo I, Dierssen-Sotos T, Palazuelos C, P\u00e9rez-G\u00f3mez B, Lope V, Tusquets I et al (2016) The use of antihypertensive medication and the risk of breast cancer in a case-control study in a Spanish population: the MCC-Spain Study. PLoS One 11(8):e0159672","DOI":"10.1371\/journal.pone.0159672"},{"key":"8930_CR48","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","volume":"173","author":"CI Li","year":"2013","unstructured":"Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE (2013) Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 173:1629\u20131637","journal-title":"JAMA Intern Med"},{"key":"8930_CR49","doi-asserted-by":"crossref","unstructured":"Grimaldi-Bensouda L, Klungel O, Kurz X, de Groot MC, Maciel Afonso AS, de Bruin ML et al (2016) Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open 6(1):e009147","DOI":"10.1136\/bmjopen-2015-009147"},{"key":"8930_CR50","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1055-9965.EPI-17-0096","volume":"26","author":"TM Brasky","year":"2017","unstructured":"Brasky TM, Krok-Schoen JL, Liu J, Chlebowski RT, Freudenheim JL, Lavasani S et al (2017) Use of calcium channel blockers and breast cancer risk in the Women\u2019s health initiative. Cancer Epidemiol Biomarkers Prev 26:1345\u20131348","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"8930_CR51","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/rheumatology\/36.4.426","volume":"36","author":"RH Straub","year":"1997","unstructured":"Straub RH, Zeuner M, Lock G, Scholmerich J, Lang B (1997) High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol 36:426\u2013432","journal-title":"Br J Rheumatol"},{"key":"8930_CR52","doi-asserted-by":"publisher","first-page":"25998","DOI":"10.1038\/srep25998","volume":"6","author":"M Wang","year":"2016","unstructured":"Wang M, Wu X, Chai F, Zhang Y, Jiang J (2016) Plasma prolactin and breast cancer risk: a meta- analysis. Sci Rep 6:25998","journal-title":"Sci Rep"},{"key":"8930_CR53","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1002\/art.21261","volume":"52","author":"J Wipff","year":"2005","unstructured":"Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J et al (2005) Prevalence of Barrett\u2019s esophagus in systemic sclerosis. Arthritis Rheum 52:2882\u20132888","journal-title":"Arthritis Rheum"},{"key":"8930_CR54","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/rheumatology\/ker110","volume":"50","author":"J Wipff","year":"2011","unstructured":"Wipff J, Coriat R, Masciocchi M, Caramaschi P, Derk CT, Hachulla E et al (2011) Outcomes of Barrett\u2019s oesophagus related to systemic sclerosis: a 3-year EULAR scleroderma trials and research prospective follow-up study. Rheumatology 50:1440\u20131444","journal-title":"Rheumatology"},{"key":"8930_CR55","doi-asserted-by":"publisher","first-page":"625","DOI":"10.14740\/jocmr2606w","volume":"8","author":"N Zeineddine","year":"2016","unstructured":"Zeineddine N, Khoury LE, Mosak J (2016) Systemic sclerosis and malignancy: a review of current data. Journal of Clinical Medicine Research 8:625\u2013632","journal-title":"Journal of Clinical Medicine Research"},{"issue":"Suppl 3","key":"8930_CR56","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.5152\/eurjrheum.2020.19104","volume":"7","author":"C Bruni","year":"2020","unstructured":"Bruni C, Furst DE (2020) The burning question: To use or not to use cyclophosphamide in systemic sclerosis. Eur J Rheumatol 7(Suppl 3):S237\u2013S241","journal-title":"Eur J Rheumatol"},{"issue":"2","key":"8930_CR57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/bjd.19549","volume":"184","author":"C Lertphanichkul","year":"2021","unstructured":"Lertphanichkul C, Smith GP (2021) Evaluation of malignancy risk in scleroderma by antibody profile. Br J Dermatol 184(2):369\u2013371","journal-title":"Br J Dermatol"},{"key":"8930_CR58","first-page":"6230138","volume":"2017","author":"M Colaci","year":"2017","unstructured":"Colaci M, Giuggioli D, Vacchi C, Ferri C (2017) Haematological malignancies in systemic sclerosis patients: case reports and review of the world literature. Case Rep Rheumatol 2017:6230138","journal-title":"Case Rep Rheumatol"},{"issue":"1","key":"8930_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000314634","volume":"57","author":"Z Szekanecz","year":"2011","unstructured":"Szekanecz Z, Szekanecz E, Bak\u00f3 G, Shoenfeld Y (2011) Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology 57(1):3\u201310","journal-title":"Gerontology"},{"issue":"1","key":"8930_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-009-1286-9","volume":"29","author":"S Vettori","year":"2010","unstructured":"Vettori S, Stibano S, Mascolo M, Ilardi G, Valentini G (2010) Non-Hodgkin\u2019s lymphoma in systemic sclerosis: case and literature review. Clin Rheumatol 29(1):1\u20136","journal-title":"Clin Rheumatol"},{"issue":"4","key":"8930_CR61","first-page":"637","volume":"32","author":"CT Derk","year":"2005","unstructured":"Derk CT, Rasheed M, Spiegel JR, Jimenez SA (2005) Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol 32(4):637\u2013641","journal-title":"J Rheumatol"},{"issue":"8","key":"8930_CR62","first-page":"1179","volume":"77","author":"T Igusa","year":"2018","unstructured":"Igusa T, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L et al (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77(8):1179\u20131186","journal-title":"Ann Rheum Dis"},{"key":"8930_CR63","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/art.27549","volume":"16","author":"AA Shah","year":"2010","unstructured":"Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies. Arthritis Rheum 16:2787\u20132795","journal-title":"Arthritis Rheum"},{"issue":"7","key":"8930_CR64","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3899\/jrheum.101144","volume":"38","author":"P Air\u00f2","year":"2011","unstructured":"Air\u00f2 P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F (2011) Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38(7):1329\u20131334","journal-title":"J Rheumatol"},{"issue":"5","key":"8930_CR65","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/1346-8138.12827","volume":"42","author":"R Saigusa","year":"2015","unstructured":"Saigusa R, Asano Y, Nakamura K, Miura S, Ichimura Y, Takahashi T et al (2015) Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis. J Dermatol 42(5):524\u2013527","journal-title":"J Dermatol"},{"issue":"1","key":"8930_CR66","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar4486","volume":"16","author":"P Moinzadeh","year":"2014","unstructured":"Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP et al (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16(1):R53","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"8930_CR67","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.39022","volume":"67","author":"AA Shah","year":"2015","unstructured":"Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM (2015) Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol 67(4):1053\u20131061","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"8930_CR68","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3899\/jrheum.160817","volume":"44","author":"MG Lazzaroni","year":"2017","unstructured":"Lazzaroni MG, Cavazzana I, Colombo E, Dobrota R, Hernandez J, Hesselstrand R et al (2017) Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR Scleroderma Trials and Research cohort and possible recommendations for screening. J Rheumatol 44(5):639\u2013647","journal-title":"J Rheumatol"},{"key":"8930_CR69","doi-asserted-by":"crossref","unstructured":"Watad A, McGonagle D, Bragazzi NL, Tiosano S, Comaneshter D, Shoenfeld Y et al (2019) Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. Oncoimmunology 8(6):e1588084","DOI":"10.1080\/2162402X.2019.1588084"},{"issue":"4","key":"8930_CR70","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3899\/jrheum.160867","volume":"44","author":"AM Hoffmann-Vold","year":"2017","unstructured":"Hoffmann-Vold AM, Midtvedt \u00d8, Tenn\u00f8e AH, Garen T, Lund MB, Aal\u00f8kken TM et al (2017) Cardiopulmonary disease development in anti-RNA polymerase III-positive systemic sclerosis: comparative analyses from an unselected, prospective patient cohort. J Rheumatol 44(4):459\u2013465","journal-title":"J Rheumatol"},{"key":"8930_CR71","doi-asserted-by":"crossref","unstructured":"Bernal-Bello D, de Tena JG, Guill\u00e9n-Del Castillo A, Selva-O\u2019Callaghan A, Callejas-Moraga EL, Mar\u00edn-S\u00e1nchez AM et al (2017) Novel risk factors related to cancer in scleroderma. Autoimmun Rev 16(5):461\u2013468","DOI":"10.1016\/j.autrev.2017.03.012"},{"key":"8930_CR72","unstructured":"Callejas-Moraga EL, Guill\u00e9n-Del-Castillo A, Mar\u00edn-S\u00e1nchez AM, Roca-Herrera M, Balada E, Tolosa-Vilella C et al (2019) Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain. Clin Exp Rheumatol 37 Suppl 119(4):41\u201348"},{"key":"8930_CR73","doi-asserted-by":"crossref","unstructured":"Joseph CG, Darrah E, Shah AA Skora AD, Casciola-Rosen LA, Wigley FM et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152\u20137","DOI":"10.1126\/science.1246886"},{"key":"8930_CR74","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.05.002","volume":"127","author":"A Vlagea","year":"2018","unstructured":"Vlagea A, Falagan S, Gutierrez-Gutierrez G, Moreno-Rubio J, Merino M, Zambrana F et al (2018) Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol 127:42\u201349","journal-title":"Crit Rev Oncol Hematol"},{"key":"8930_CR75","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/art.1780350621","volume":"35","author":"N Rothfield","year":"1992","unstructured":"Rothfield N, Kurtzman S, Vasques-Abal D, Charron C, Daniels L, Greenberg B (1992) Association of antitopoisomerase 1 with cancer. Arthritis Rheum 35:724","journal-title":"Arthritis Rheum"},{"key":"8930_CR76","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.1780390423","volume":"39","author":"M Kuwana","year":"1996","unstructured":"Kuwana M, Fujii T, Mimori T, Kaburaki J (1996) Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis: a report of two cases. Arthritis Rheum 39:686\u2013691","journal-title":"Arthritis Rheum"},{"key":"8930_CR77","doi-asserted-by":"crossref","unstructured":"Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ et al (2017) Brief Report: Anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma. Arthritis Rheumatol","DOI":"10.1002\/art.40065"},{"key":"8930_CR78","doi-asserted-by":"crossref","unstructured":"Xu GJ, Shah AA, Li MZ, Xu Q, Rosen A, Casciola-Rosen L et al (2016) Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci USA 113(47):E7526-e7534","DOI":"10.1073\/pnas.1615990113"},{"issue":"12","key":"8930_CR79","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/1744666X.2021.1847641","volume":"16","author":"GE Fragoulis","year":"2020","unstructured":"Fragoulis GE, Daoussis D, Pagkopoulou E, Garyfallos A, Kitas GD, Dimitroulas T (2020) Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients. Expert Rev Clin Immunol 16(12):1105\u20131113","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"8930_CR80","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.autrev.2017.05.023","volume":"16","author":"M Boonstra","year":"2017","unstructured":"Boonstra M, Huizinga TWJ, de Vries-Bouwstra JK (2017) Auto-antibodies and cancer in systemic sclerosis. Autoimmun Rev 16(8):883\u2013884","journal-title":"Autoimmun Rev"},{"issue":"3","key":"8930_CR81","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2217\/fon.10.6","volume":"6","author":"C Atalay","year":"2010","unstructured":"Atalay C, Dogan L, Atalay G (2010) Anti-CENP-B antibodies are associated with prolonged survival in breast cancer. Future Oncol 6(3):471\u2013477","journal-title":"Future Oncol"},{"issue":"2","key":"8930_CR82","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.41493","volume":"73","author":"CA Mecoli","year":"2021","unstructured":"Mecoli CA, Adler BL, Yang Q, Hummers LK, Rosen A, Casciola-Rosen L et al (2021) Cancer in systemic sclerosis: analysis of antibodies against components of the Th\/To complex. Arthritis Rheumatol 73(2):315\u2013323","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"8930_CR83","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909 (Epub 2016 Nov 9 PMID: 27941129)","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"8930_CR84","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa055120 (PMID: 16790698)","journal-title":"N Engl J Med"},{"issue":"8","key":"8930_CR85","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1007\/s10067-021-05794-5","volume":"40","author":"X Ma","year":"2021","unstructured":"Ma X, Tang R, Luo M, Zeng Z, Shi Y, Tang B et al (2021) Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Clin Rheumatol 40(8):3185\u20133193. https:\/\/doi.org\/10.1007\/s10067-021-05794-5 (Epub 2021 Jun 2 PMID: 34080081)","journal-title":"Clin Rheumatol"},{"issue":"1","key":"8930_CR86","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N et al (2008) Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35(1):100\u2013105 (Epub 2007 Oct 15 PMID: 17937462)","journal-title":"J Rheumatol"},{"issue":"7","key":"8930_CR87","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","volume":"87","author":"LB Travis","year":"1995","unstructured":"Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF et al (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma. J Natl Cancer Inst 87(7):524\u2013530. https:\/\/doi.org\/10.1093\/jnci\/87.7.524 (PMID: 7707439)","journal-title":"J Natl Cancer Inst"},{"key":"8930_CR88","doi-asserted-by":"publisher","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7\u00a0(Epub 2016 Jul 25. PMID: 27469583; PMCID: PMC5014629)","DOI":"10.1016\/S2213-2600(16)30152-7"},{"issue":"12","key":"8930_CR89","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1111\/j.1600-6143.2005.01125.x.PMID:16303010bic","volume":"5","author":"R Robson","year":"2005","unstructured":"Robson R, Cecka JM, Opelz G, Budde M, Sacks S (2005) Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5(12):2954\u20132960. https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01125.x.PMID:16303010bic","journal-title":"Am J Transplant"},{"issue":"2","key":"8930_CR90","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.transproceed.2008.12.013","volume":"41","author":"W Bichari","year":"2009","unstructured":"Bichari W, Bartiromo M, Mohey H, Afiani A, Burnot A, Maillard N et al (2009) Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transplant Proc 41(2):672\u2013673. https:\/\/doi.org\/10.1016\/j.transproceed.2008.12.013 (PMID: 19328953)","journal-title":"Transplant Proc"},{"issue":"32","key":"8930_CR91","doi-asserted-by":"publisher","first-page":"33849","DOI":"10.18632\/oncotarget.5292.PMID:26460822;PMCID:PMC4741807","volume":"6","author":"GM Crane","year":"2015","unstructured":"Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC et al (2015) Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget 6(32):33849\u201333866. https:\/\/doi.org\/10.18632\/oncotarget.5292.PMID:26460822;PMCID:PMC4741807","journal-title":"Oncotarget"},{"issue":"12","key":"8930_CR92","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/archdermatol.2009.276.PMID:20026847;PMCID:PMC4103015","volume":"145","author":"JD Brewer","year":"2009","unstructured":"Brewer JD, Colegio OR, Phillips PK, Roenigk RK, Jacobs MA, Van de Beek D et al (2009) Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 145(12):1391\u20131396. https:\/\/doi.org\/10.1001\/archdermatol.2009.276.PMID:20026847;PMCID:PMC4103015","journal-title":"Arch Dermatol"},{"issue":"11","key":"8930_CR93","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3899\/jrheum.100041","volume":"37","author":"MS Krathen","year":"2010","unstructured":"Krathen MS, Gottlieb AB, Mease PJ (2010) Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol 37(11):2205\u20132215. https:\/\/doi.org\/10.3899\/jrheum.100041 (Epub 2010 Sep 1 PMID: 20810498)","journal-title":"J Rheumatol"},{"issue":"4","key":"8930_CR94","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000521","volume":"1","author":"ML Sanders","year":"2015","unstructured":"Sanders ML, Karnes JH, Denny JC, Roden DM, Ikizler TA, Birdwell KA (2015) Clinical and genetic factors associated with cutaneous squamous cell carcinoma in kidney and heart transplant recipients. Transplant Direct 1(4):e13. https:\/\/doi.org\/10.1097\/TXD.0000000000000521","journal-title":"Transplant Direct"},{"issue":"3","key":"8930_CR95","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jgh.14533","volume":"34","author":"C Ye","year":"2019","unstructured":"Ye C, Dai SX (2019) Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 34(3):507\u2013516. https:\/\/doi.org\/10.1111\/jgh.14533","journal-title":"J Gastroenterol Hepatol"},{"key":"8930_CR96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jocn.2021.03.015","volume":"88","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Wang M, Xu L, Jiang B, Jin T, Shi T et al (2021) Cancer occurrence following azathioprine treatment in myasthenia gravis patients: a systematic review and meta-analysis. J Clin Neurosci 88:70\u201374. https:\/\/doi.org\/10.1016\/j.jocn.2021.03.015","journal-title":"J Clin Neurosci"},{"key":"8930_CR97","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/annrheumdis-2021-eular.2701","volume":"80","author":"L Verardi","year":"2021","unstructured":"Verardi L, De Lorenzis E, Natalello G, Gigante L, D\u2019Agostino MA, Bosello SL (2021) POS0289 Cancer risk in immunosuppressed scleroderma patients: a propensity score matching analysis. Ann Rheum Dis 80:370","journal-title":"Ann Rheum Dis"},{"key":"8930_CR98","doi-asserted-by":"publisher","unstructured":"Raaschou P, Simard JF, Holmqvist M, Askling J, ARTIS Study Group (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346:f1939.\u00a0https:\/\/doi.org\/10.1136\/bmj.f1939\u00a0(PMID: 23568792)","DOI":"10.1136\/bmj.f1939"},{"key":"8930_CR99","doi-asserted-by":"publisher","unstructured":"Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML et al (2017) Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 76(2):386\u2013391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209285\u00a0(Epub 2016 Jun 15. PMID: 27307502; PMCID: PMC5284347)","DOI":"10.1136\/annrheumdis-2016-209285"},{"key":"8930_CR100","doi-asserted-by":"publisher","unstructured":"Wadstr\u00f6m H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med 177(11):1605\u20131612.\u00a0https:\/\/doi.org\/10.1001\/jamainternmed.2017.4332\u00a0(PMID: 28975211; PMCID: PMC5710271)","DOI":"10.1001\/jamainternmed.2017.4332"},{"issue":"10","key":"8930_CR101","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M et al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963\u2013974. https:\/\/doi.org\/10.1016\/S2213-2600(20)30318-0","journal-title":"Lancet Respir Med"},{"issue":"26","key":"8930_CR102","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380(26):2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076 (Epub 2019 May 20 PMID: 31112379)","journal-title":"N Engl J Med"},{"issue":"2","key":"8930_CR103","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15(2):143\u2013155. https:\/\/doi.org\/10.1016\/S1470-2045(13)70586-2 (Epub 2014 Jan 9 PMID: 24411639)","journal-title":"Lancet Oncol"},{"key":"8930_CR104","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/rheumatology\/35.8.732","volume":"35","author":"CM Artlett","year":"1996","unstructured":"Artlett CM, Black CM, Briggs DC, Stevens CO, Welsh KI (1996) Telomere reduction in scleroderma patients: a possible cause for chromosomal instability. Br J Rheumatol 35:732\u2013737","journal-title":"Br J Rheumatol"},{"key":"8930_CR105","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/ijms19020482","volume":"19","author":"K Cleal","year":"2018","unstructured":"Cleal K, Norris K, Baird D (2018) Telomere length dynamics and the evolution of cancer genome architecture. Int J Mol Sci 19:482","journal-title":"Int J Mol Sci"},{"key":"8930_CR106","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1073\/pnas.0811332106","volume":"106","author":"H Fujji","year":"2009","unstructured":"Fujji H, Shao L, Colmegna I, Goronzy JJ, Weyand CM (2009) Telomerase insufficiency in rheumatoid arthritis. Proc Natl Acad Sci U S A 106:4360\u20134365","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"8930_CR107","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/annrheumdis-2020-218918","volume":"80","author":"BL Adler","year":"2021","unstructured":"Adler BL, Boin F, Wolters PJ, Bingham CO, Shah AA, Greider C et al (2021) Autoantibodies targeting telomere-associated proteins in systemic sclerosis. Ann Rheum Dis 80(7):912\u2013919","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"8930_CR108","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/1756-185X.13924","volume":"23","author":"L Zhang","year":"2020","unstructured":"Zhang L, Wu H, Zhao M, Lu Q (2020) Meta-analysis of differentially expressed microRNAs in systemic sclerosis. Int J Rheum Dis 23(10):1297\u20131304. https:\/\/doi.org\/10.1111\/1756-185X.13924","journal-title":"Int J Rheum Dis"},{"key":"8930_CR109","doi-asserted-by":"publisher","unstructured":"Zhu H, Luo H, Li Y, Zhou Y, Jiang Y, Chai J et al (2013) MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J Clin Immunol 33(6):1100\u20139. https:\/\/doi.org\/10.1007\/s10875-013-9896-z","DOI":"10.1007\/s10875-013-9896-z"},{"issue":"20","key":"8930_CR110","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.omtn.2020.03.003","volume":"5","author":"D Bautista-S\u00e1nchez","year":"2020","unstructured":"Bautista-S\u00e1nchez D, Arriaga-Canon C, Pedroza-Torres A, De La Rosa-Vel\u00e1zquez IA, Gonz\u00e1lez-Barrios R, Contreras-Espinosa L et al (2020) The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther Nucleic Acids 5(20):409\u2013420","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"8930_CR111","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41389-019-0151-1","volume":"8","author":"Y Yang","year":"2019","unstructured":"Yang Y, Li Z, Yuan H, Ji W, Wang K, Lu T et al (2019) Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. Oncogenesis 8(9):50","journal-title":"Oncogenesis"},{"key":"8930_CR112","doi-asserted-by":"publisher","unstructured":"Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, KelnarK, Ovcharenko D et al (2007) The let-7 microRNA represses cellproliferation pathways in human cells.Cancer Res 67(16):7713\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1083","DOI":"10.1158\/0008-5472.CAN-07-1083"},{"key":"8930_CR113","doi-asserted-by":"crossref","unstructured":"Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, GibsonKF et al (2010) Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 182:220\u20139","DOI":"10.1164\/rccm.200911-1698OC"},{"key":"8930_CR114","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00403-012-1287-4","volume":"305","author":"M Etoh","year":"2013","unstructured":"Etoh M, Jinnin M, Makino K, Yamane K, Nakayama W, Aoi J et al (2013) microRNA-7 down-regulation mediates excessive collagen expressionin localized scleroderma. Arch Dermatol Res 305:9\u201315","journal-title":"Arch Dermatol Res"},{"key":"8930_CR115","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fimmu.2018.00449","volume":"9","author":"M Dolcino","year":"2018","unstructured":"Dolcino M, Pelosi A, Fiore PF, Patuzzo G, Tinazzi E, Lunardi C et al (2018) Gene profiling in patients with systemic sclerosis reveals the presence of oncogenic gene signatures. Front Immunol 9:449","journal-title":"Front Immunol"},{"key":"8930_CR116","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.autrev.2015.05.004","volume":"14","author":"GC Wu","year":"2015","unstructured":"Wu GC, Pan HF, Leng RX, Wang DG, Li XP, Li XM et al (2015) Emerging role of long noncoding RNAs in autoimmune diseases. Autoimmun Rev 14:798\u2013805","journal-title":"Autoimmun Rev"},{"issue":"3","key":"8930_CR117","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/jcm8030320","volume":"8","author":"M Dolcino","year":"2019","unstructured":"Dolcino M, Tinazzi E, Puccetti A, Lunardi C (2019) In systemic sclerosis, a unique long non coding RNA regulates genes and pathways involved in the three main features of the disease (vasculopathy, fibrosis and autoimmunity) and in carcinogenesis. J Clin Med 8(3):320","journal-title":"J Clin Med"},{"key":"8930_CR118","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/art.1780401211","volume":"40","author":"D Stanek","year":"1997","unstructured":"Stanek D, Vencovsk\u00fd J, Kafkov\u00e1 J, Raska I (1997) Heterogenous nuclear RNP C1 and C2 core proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis. Arthritis Rheum 40:2172\u20132177","journal-title":"Arthritis Rheum"},{"key":"8930_CR119","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ncrna3030024","volume":"3","author":"DS Sutaria","year":"2017","unstructured":"Sutaria DS, Jiang J, Azevedo-Pouly ACP, Lee EJ, Lerner MR, Brackett DJ et al (2017) Expression profiling identifies the noncoding processed transcript of HNRNPU with proliferative properties in pancreatic ductal adenocarcinoma. Noncoding RNA 3:24. https:\/\/doi.org\/10.3390\/ncrna3030024","journal-title":"Noncoding RNA"},{"key":"8930_CR120","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1021\/acs.jproteome.6b00156","volume":"15","author":"YP Kang","year":"2016","unstructured":"Kang YP, Lee SB, Lee JM (2016) Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J Proteome Res 15:1717\u20131724","journal-title":"J Proteome Res"},{"issue":"1","key":"8930_CR121","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000183.","volume":"4","author":"YD Zhao","year":"2017","unstructured":"Zhao YD, Yin L, Archer S (2017) Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study. BMJ Open Respir Res 4(1):e000183. https:\/\/doi.org\/10.1136\/bmjresp-2017-000183.","journal-title":"BMJ Open Respir Res"},{"key":"8930_CR122","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrc1478","volume":"4","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891\u2013899. https:\/\/doi.org\/10.1038\/nrc1478","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"8930_CR123","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ccr.2006.08.015","volume":"10","author":"PT Schumacker","year":"2006","unstructured":"Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10(3):175\u2013176. https:\/\/doi.org\/10.1016\/j.ccr.2006.08.015","journal-title":"Cancer Cell"},{"key":"8930_CR124","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0190-9622(93)70014-K","volume":"28","author":"DF Murrel","year":"1993","unstructured":"Murrel DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78\u201385","journal-title":"J Am Acad Dermatol"},{"key":"8930_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101122","volume":"25","author":"L Doridot","year":"2019","unstructured":"Doridot L, Jeljeli M, Ch\u00eane C, Batteux F (2019) Implication of oxidative stress in the pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis. Redox Biol 25:101122. https:\/\/doi.org\/10.1016\/j.redox.2019.101122","journal-title":"Redox Biol"},{"key":"8930_CR126","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/ard.2006.067504)","volume":"66","author":"A Servettaz","year":"2007","unstructured":"Servettaz A, Guilpain P, Goulvestre C (2007) Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 66:1202\u20131209. https:\/\/doi.org\/10.1136\/ard.2006.067504)","journal-title":"Ann Rheum Dis"},{"key":"8930_CR127","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.autrev.2014.08.028","volume":"13","author":"Z Yan","year":"2014","unstructured":"Yan Z, Kui Z, Ping Z (2014) Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. Autoimmun Rev 13:1020\u20131025. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.028","journal-title":"Autoimmun Rev"},{"key":"8930_CR128","doi-asserted-by":"publisher","first-page":"7123","DOI":"10.4049\/jimmunol.172.11.7123","volume":"172","author":"Y Asano","year":"2004","unstructured":"Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K (2004) Phosphatidylinositol 3-kinase is involved in alpha2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 172:7123\u20137135. https:\/\/doi.org\/10.4049\/jimmunol.172.11.7123","journal-title":"J Immunol"},{"key":"8930_CR129","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","volume":"59","author":"F Janku","year":"2017","unstructured":"Janku F (2017) Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients. Cancer Treat Rev 59:93\u2013101. https:\/\/doi.org\/10.1016\/j.ctrv.2017.07.005","journal-title":"Cancer Treat Rev"},{"key":"8930_CR130","doi-asserted-by":"publisher","unstructured":"Li B, Selmi C, Tang R, Gershwin ME, Ma X (2018) The microbiome and autoimmunity: a paradigm from the gut-liver axis. Cell Mol Immunol. 2018 Jun;15(6):595\u2013609.\u00a0https:\/\/doi.org\/10.1038\/cmi.2018.7\u00a0(Epub 2018 Apr 30. PMID: 29706647; PMCID: PMC6079090)","DOI":"10.1038\/cmi.2018.7"},{"issue":"1","key":"8930_CR131","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000134","volume":"4","author":"ER Volkmann","year":"2017","unstructured":"Volkmann ER, Hoffmann-Vold AM, Chang YL, Jacobs JP, Tillisch K, Mayer EA et al (2017) Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol 4(1):e000134. https:\/\/doi.org\/10.1136\/bmjgast-2017-000134","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"8930_CR132","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13073-021-00853-7)","volume":"13","author":"DR Plichta","year":"2021","unstructured":"Plichta DR, Somani J, Pichaud M, Wallace ZS, Fernandes AD, Perugino CA et al (2021) Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. Genome Med 13(1):35. https:\/\/doi.org\/10.1186\/s13073-021-00853-7)","journal-title":"Genome Med"},{"key":"8930_CR133","doi-asserted-by":"crossref","unstructured":"Xin Yu J, Hubbard-Lucey VM, Tang J (2019) Immuno-oncology drug development goes global. Nat Rev Drug Discov 18:899\u2013900","DOI":"10.1038\/d41573-019-00167-9"},{"issue":"2","key":"8930_CR134","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"26","key":"8930_CR135","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532","journal-title":"N Engl J Med"},{"issue":"4","key":"8930_CR136","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fonc.2014.00385.PMID:25642417;PMCID:PMC4295550","volume":"15","author":"MK Callahan","year":"2015","unstructured":"Callahan MK, Postow MA, Wolchok JD (2015) CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol 15(4):385. https:\/\/doi.org\/10.3389\/fonc.2014.00385.PMID:25642417;PMCID:PMC4295550","journal-title":"Front Oncol"},{"key":"8930_CR137","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.1996.tb00919.x","volume":"153","author":"CA Chambers","year":"1996","unstructured":"Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S et al (1996) The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 153:27\u201346","journal-title":"Immunol Rev"},{"issue":"10","key":"8930_CR138","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.humimm.2010.07.007","volume":"71","author":"S Laurent","year":"2010","unstructured":"Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A et al (2010) CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 71(10):934\u2013941","journal-title":"Hum Immunol"},{"key":"8930_CR139","doi-asserted-by":"publisher","unstructured":"Arasanz H, Gato-Ca\u00f1as M, Zuazo M, Iba\u00f1ez-Vea M, Breckpot K, Kochan G et al (2017) D. PD1 signal transduction pathways in T cells. Oncotarget 8(31):51936\u201351945.\u00a0https:\/\/doi.org\/10.18632\/oncotarget.17232\u00a0(PMID: 28881701; PMCID: PMC5584302)","DOI":"10.18632\/oncotarget.17232"},{"issue":"1","key":"8930_CR140","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clim.2013.11.007","volume":"150","author":"MJ Olde Nordkamp","year":"2014","unstructured":"Olde Nordkamp MJ, Koeleman BP, Meyaard L (2014) Do inhibitory immune receptors play a role in the etiology of autoimmune disease? Clin Immunol 150(1):31\u201342. https:\/\/doi.org\/10.1016\/j.clim.2013.11.007 (Epub 2013 Nov 19 PMID: 24333531)","journal-title":"Clin Immunol"},{"key":"8930_CR141","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"issue":"1","key":"8930_CR142","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"10","key":"8930_CR143","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2(10):1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"issue":"3","key":"8930_CR144","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","volume":"17","author":"S Antonia","year":"2016","unstructured":"Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A et al (2016) Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17(3):299\u2013308","journal-title":"Lancet Oncol"},{"issue":"10","key":"8930_CR145","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2(10):1346\u20131353","journal-title":"JAMA Oncol"},{"issue":"11","key":"8930_CR146","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134. https:\/\/doi.org\/10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"issue":"10","key":"8930_CR147","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","volume":"76","author":"R Belkhir","year":"2017","unstructured":"Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B et al (2017) Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76(10):1747\u20131750","journal-title":"Ann Rheum Dis"},{"key":"8930_CR148","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","volume":"5","author":"Y Toi","year":"2019","unstructured":"Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T et al (2019) Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol 5:376\u2013383","journal-title":"JAMA Oncol"},{"issue":"12","key":"8930_CR149","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40264-019-00864-9","volume":"42","author":"CM Stach","year":"2019","unstructured":"Stach CM, Sloan VS, Woodworth TG, Kilgallen B, Furst DE (2019) Rheumatology Common Toxicity Criteria (RCTC): an update reflecting real-world use. Drug Saf 42(12):1499\u20131506","journal-title":"Drug Saf"},{"key":"8930_CR150","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","volume":"5","author":"JL Godwin","year":"2017","unstructured":"Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R et al (2017) Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer 5:40","journal-title":"J Immunother Cancer"},{"issue":"2","key":"8930_CR151","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168(2):121\u2013130","journal-title":"Ann Intern Med"},{"key":"8930_CR152","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91:21\u201329","journal-title":"Eur J Cancer"},{"key":"8930_CR153","doi-asserted-by":"crossref","unstructured":"Cortellni A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M et al (2019) Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 24(6):e327-e337","DOI":"10.1634\/theoncologist.2018-0618"},{"key":"8930_CR154","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.40397","volume":"70","author":"MD Richter","year":"2018","unstructured":"Richter MD, Pinkston O, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U (2018) Brief Report: Cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience. Arthritis Rheumatol 70:356\u2013360. https:\/\/doi.org\/10.1002\/art.40397","journal-title":"Arthritis Rheumatol"},{"key":"8930_CR155","doi-asserted-by":"publisher","unstructured":"Leonardi GC, Gainor JF, Altan M, Kracets S, Dahlberg SE, Gedmintas L et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905\u201312. https:\/\/doi.org\/10.1200\/JCO.2017.77.0305","DOI":"10.1200\/JCO.2017.77.0305"},{"issue":"8","key":"8930_CR156","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","volume":"70","author":"S Hoa","year":"2021","unstructured":"Hoa S, Laaouad L, Roberts J, Ennis D, Ye C, Al Jumaily K et al (2021) Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunol Immunother 70(8):2197\u20132207","journal-title":"Cancer Immunol Immunother"},{"key":"8930_CR157","doi-asserted-by":"publisher","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","volume":"17","author":"LC Kennedy","year":"2019","unstructured":"Kennedy LC, Bhatia S, Thompson JA, Grivas P (2019) Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Canc Netw 17:750\u2013757","journal-title":"J Natl Compr Canc Netw"},{"key":"8930_CR158","doi-asserted-by":"crossref","unstructured":"Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M et al (2020) Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev 19:102595","DOI":"10.1016\/j.autrev.2020.102595"},{"key":"8930_CR159","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol 71:2100\u20132111","journal-title":"Arthritis Rheumatol"},{"key":"8930_CR160","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368\u2013376","journal-title":"Ann Oncol"},{"key":"8930_CR161","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:2872\u20132878","journal-title":"J Clin Oncol"},{"key":"8930_CR162","doi-asserted-by":"crossref","unstructured":"Fuc\u00e0 G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M et al (2019) Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 4:e000457","DOI":"10.1136\/esmoopen-2018-000457"},{"key":"8930_CR163","doi-asserted-by":"crossref","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S et al (2019) Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 17:255\u201389","DOI":"10.6004\/jnccn.2019.0013"},{"key":"8930_CR164","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.185.3.393","volume":"185","author":"PA van der Merwe","year":"1997","unstructured":"van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ (1997) CD80 (B7\u20131) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 185:393\u2013403","journal-title":"J Exp Med"},{"key":"8930_CR165","unstructured":"US National Library of Medicine (2015) ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00442611https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02161406"},{"key":"8930_CR166","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173:945\u2013954","journal-title":"J Immunol"},{"key":"8930_CR167","doi-asserted-by":"crossref","unstructured":"Yu x, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B et al (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10:48\u201357","DOI":"10.1038\/ni.1674"},{"key":"8930_CR168","doi-asserted-by":"crossref","unstructured":"Zhang, J. Bi, X. Zheng, Chen Y, Wang H, Wu W et al (2018) Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19(7):723\u2013732","DOI":"10.1038\/s41590-018-0132-0"},{"key":"8930_CR169","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"NA Manieri","year":"2017","unstructured":"Manieri NA, Chiang EY, Grogan JL (2017) TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol 38:20\u201328","journal-title":"Trends Immunol"},{"issue":"8","key":"8930_CR170","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.4049\/jimmunol.1700407","volume":"200","author":"KO Dixon","year":"2018","unstructured":"Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T et al (2018) Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol 200(8):3000\u20133007","journal-title":"J Immunol"},{"key":"8930_CR171","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/eji.201041136","volume":"41","author":"SD Levin","year":"2011","unstructured":"Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM et al (2011) Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol 41:902\u2013915","journal-title":"Eur J Immunol"},{"issue":"5","key":"8930_CR172","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.4049\/jimmunol.0901652","volume":"184","author":"S Kasagi","year":"2010","unstructured":"Kasagi S, Kawano S, Okazaki T, Honjo T, Morinobu A, Hatachi S et al (2010) Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB\/W F1 mice. J Immunol 184(5):2337\u20132347","journal-title":"J Immunol"},{"issue":"2","key":"8930_CR173","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor. Immunity 11(2):141\u2013151","journal-title":"Immunity"},{"issue":"6","key":"8930_CR174","doi-asserted-by":"publisher","first-page":"39105","DOI":"10.1038\/srep39105","volume":"14","author":"J Zhou","year":"2016","unstructured":"Zhou J, Jin JO, Kawai T, Yu Q (2016) Endogenous programmed death ligand-1 restrains the development and onset of Sjgren\u2019s syndrome in non-obese diabetic mice. Sci Rep 14(6):39105. https:\/\/doi.org\/10.1038\/srep39105","journal-title":"Sci Rep"},{"key":"8930_CR175","first-page":"75","volume":"410","author":"K Chamoto","year":"2017","unstructured":"Chamoto K, Al-Habsi M, Honjo T (2017) Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol 410:75\u201397","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"8930_CR176","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41551-019-0360-0","volume":"3","author":"P Zhao","year":"2019","unstructured":"Zhao P, Wang P, Dong S, Zhou Z, Cao Y, Yagita H et al (2019) Depletion of PD-1-positive cells ameliorates autoimmune disease. Nat Biomed Eng 3(4):292\u2013305","journal-title":"Nat Biomed Eng"},{"key":"8930_CR177","doi-asserted-by":"crossref","unstructured":"Wang l, Rubistein R, Lines JL, Wasiuk A, Ahonen C, Guo Y et al (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577\u2013592","DOI":"10.1084\/jem.20100619"},{"key":"8930_CR178","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/ng2046","volume":"39","author":"M Fanciulli","year":"2007","unstructured":"Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L et al (2007) FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 39:721\u2013723","journal-title":"Nat Genet"},{"issue":"4","key":"8930_CR179","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/cancers13040860","volume":"13","author":"A Paderi","year":"2021","unstructured":"Paderi A, Giorgione R, Giommoni E, Mela MM, Rossi V, Doni L et al (2021) Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Cancers (Basel) 13(4):860. https:\/\/doi.org\/10.3390\/cancers13040860","journal-title":"Cancers (Basel)"},{"issue":"5","key":"8930_CR180","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.3390\/curroncol28050283","volume":"28","author":"A Paderi","year":"2021","unstructured":"Paderi A, Fancelli S, Caliman E, Pillozzi S, Gambale E, Mela MM et al (2021) Safety of immune checkpoint inhibitors in elderly patients: an observational study. Curr Oncol 28(5):3259\u20133267. https:\/\/doi.org\/10.3390\/curroncol28050283","journal-title":"Curr Oncol"},{"issue":"3","key":"8930_CR181","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/immuno1030017","volume":"1","author":"E Giommoni","year":"2021","unstructured":"Giommoni E, Giorgione R, Paderi A, Pellegrini E, Gambale E, Marini A et al (2021) Eosinophil count as predictive biomarker of immune-related adverse events (irAEs) in immune checkpoint inhibitors (ICIs) therapies in oncological patients. Immuno 1(3):253\u2013263. https:\/\/doi.org\/10.3390\/immuno1030017","journal-title":"Immuno"},{"issue":"6","key":"8930_CR182","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/BOR.0000000000000222","volume":"27","author":"AA Shah","year":"2015","unstructured":"Shah AA, Casciola-Rosen L (2015) Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol 27(6):563\u2013570","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"8930_CR183","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.rdc.2020.03.002","volume":"46","author":"E Weeding","year":"2020","unstructured":"Weeding E, Casciola-Rosen L, Shah AA (2020) Cancer and scleroderma. Rheum Dis Clin North Am 46(3):551\u2013564","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08930-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-022-08930-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08930-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T06:06:48Z","timestamp":1668838008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-022-08930-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":183,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8930"],"URL":"https:\/\/doi.org\/10.1007\/s12016-022-08930-4","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"10 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}